Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable

Implications for radiochemotherapy

G. Cartei, E. Colombrino, M. C. Sanzari, M. Plebani, M. Micucci, F. Fiorica, T. Glraldi, F. Zustovich, F. Cartel

Research output: Contribution to journalArticle

Abstract

Mitomycin C (Me) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia. We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m2• When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBCindices, hemolysis, erythropoietin, liver and kidney function were studied. MCcycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity. Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m2 group (p=0.049). Basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p2 a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MCis accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy.

Original languageEnglish
Pages (from-to)362-366
Number of pages5
JournalJournal of Chemotherapy
Volume23
Issue number6
Publication statusPublished - Dec 2011

Fingerprint

Mitomycin
Chemoradiotherapy
Erythropoietin
Anemia
Pharmaceutical Preparations
Radiotherapy
Neoplasms
Hemolysis
Hematocrit
Hemoglobins
Kidney
Drug Therapy
Liver
Therapeutics

Keywords

  • Anemia
  • Chemoradiotherapy
  • Erythropoietin
  • Mitomycin C

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology
  • Medicine(all)

Cite this

Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable : Implications for radiochemotherapy. / Cartei, G.; Colombrino, E.; Sanzari, M. C.; Plebani, M.; Micucci, M.; Fiorica, F.; Glraldi, T.; Zustovich, F.; Cartel, F.

In: Journal of Chemotherapy, Vol. 23, No. 6, 12.2011, p. 362-366.

Research output: Contribution to journalArticle

Cartei, G, Colombrino, E, Sanzari, MC, Plebani, M, Micucci, M, Fiorica, F, Glraldi, T, Zustovich, F & Cartel, F 2011, 'Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: Implications for radiochemotherapy', Journal of Chemotherapy, vol. 23, no. 6, pp. 362-366.
Cartei, G. ; Colombrino, E. ; Sanzari, M. C. ; Plebani, M. ; Micucci, M. ; Fiorica, F. ; Glraldi, T. ; Zustovich, F. ; Cartel, F. / Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable : Implications for radiochemotherapy. In: Journal of Chemotherapy. 2011 ; Vol. 23, No. 6. pp. 362-366.
@article{4773e00be458477cb3ac9a02beb48a51,
title = "Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: Implications for radiochemotherapy",
abstract = "Mitomycin C (Me) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia. We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m2• When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBCindices, hemolysis, erythropoietin, liver and kidney function were studied. MCcycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity. Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m2 group (p=0.049). Basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p2 a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MCis accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy.",
keywords = "Anemia, Chemoradiotherapy, Erythropoietin, Mitomycin C",
author = "G. Cartei and E. Colombrino and Sanzari, {M. C.} and M. Plebani and M. Micucci and F. Fiorica and T. Glraldi and F. Zustovich and F. Cartel",
year = "2011",
month = "12",
language = "English",
volume = "23",
pages = "362--366",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable

T2 - Implications for radiochemotherapy

AU - Cartei, G.

AU - Colombrino, E.

AU - Sanzari, M. C.

AU - Plebani, M.

AU - Micucci, M.

AU - Fiorica, F.

AU - Glraldi, T.

AU - Zustovich, F.

AU - Cartel, F.

PY - 2011/12

Y1 - 2011/12

N2 - Mitomycin C (Me) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia. We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m2• When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBCindices, hemolysis, erythropoietin, liver and kidney function were studied. MCcycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity. Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m2 group (p=0.049). Basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p2 a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MCis accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy.

AB - Mitomycin C (Me) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia. We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m2• When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBCindices, hemolysis, erythropoietin, liver and kidney function were studied. MCcycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity. Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m2 group (p=0.049). Basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p2 a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MCis accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy.

KW - Anemia

KW - Chemoradiotherapy

KW - Erythropoietin

KW - Mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=84864916451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864916451&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 362

EP - 366

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 6

ER -